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Abstract: Breast cancer is a complex heterogeneous disease with multiple underlying causes. The
polyamines putrescine, spermidine, and spermine are polycationic molecules essential for cell prolif-
eration. Their biosynthesis is upregulated in breast cancer and they contribute to disease progression.
While elevated polyamines are linked to breast cancer cell proliferation, there is little evidence to
suggest breast cancer cells of different hormone receptor status are equally dependent on polyamines.
In this study, we characterized the responses of two breast cancer cells, ER+ (oestrogen receptor
positive) MCF-7 and ER- MDA-MB-231 cell lines, to polyamine modulation and determined the
requirement of each polyamine for cancer cell growth. The cells were exposed to DFMO (a polyamine
pathway inhibitor) at various concentrations under different conditions, after which several growth
parameters were determined. Exposure of both cell lines to DFMO induced differential growth
responses, MCF-7 cells showed greater sensitivity to polyamine pathway inhibition at various DFMO
concentrations than the MDA-MB-231 cells. Analysis of intracellular DFMO after withdrawal from
growth medium showed residual DFMO in the cells with concomitant decreases in polyamine con-
tent, ODC protein level, and cell growth. Addition of exogenous polyamines reversed the cell growth
inhibition, and this growth recovery appears to be partly dependent on the spermidine content of
the cell. Similarly, DFMO exposure inhibits the global translation state of the cells, with spermidine
addition reversing the inhibition of translation in the breast cancer cells. Taken together, these data
suggest that breast cancer cells are differentially sensitive to the antitumour effects of polyamine
depletion, thus, targeting polyamine metabolism might be therapeutically beneficial in breast cancer
management based on their subtype.
Keywords: polyamines; cell growth; breast cancer subtypes; DFMO
1. Introduction
Breast cancer is a malignant epithelial tumour of tissues of the breast including the
inner layer of the milk glands or lobules, the milk ducts, and the connective tissues [1]. It is
the second most diagnosed cancer and the fifth leading cause of cancer-related death. Breast
cancer is a complex heterogeneous disease with multiple underlying causes. Dysregulated
metabolic/signalling pathways are major drivers of cancer [2–4]. Among the metabolic
pathways that have been shown to be enhanced by various cellular and molecular processes
that lead to breast carcinogenesis is the polyamine metabolic pathway [5–8].
The polyamines are ubiquitous polycationic molecules essential for normal cell func-
tioning and are elevated in vast majority of human cancers [9–12]. In breast cancer, the
polyamine biosynthetic pathway is upregulated, causing a 3- to 6-fold increase in tumour
polyamine content compared to the normal epithelial breast tissue [13,14]. These increases
in polyamines and polyamines metabolic enzymes are associated with poor prognosis of
breast and colorectal cancers [15–17]. Similarly, many indicators of poor prognosis in breast
cancer, such as tumour size and histological grade are correlated with increased tumour
polyamine content [14], highlighting the importance of polyamines in breast carcinogenesis
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and disease progression. While elevated polyamines are associated with poor prognosis in
breast cancer, it is not clear if breast cancer cells of different hormone receptor status show
similar dependence on polyamines for continued proliferation.
The aim of this study was to characterize the growth responses of two breast cancer
cells of different subtypes (based on their hormone receptor status) to conditions that
altered their polyamine content, and to determine the sensitivity of the breast cancer
cells to the anti-tumour effect of polyamine pathway inhibition. To inhibit the polyamine
pathway, a well-known inhibitor (α-difluoromethylornithine, DFMO) of a key enzyme
(ornithine decarboxylase, ODC) in polyamine biosynthesis was used. As part of our study,
we developed a novel assay to quantify the intracellular DFMO content after cell exposure.
We also determined the requirement of each polyamine of both breast cancer cell lines
for growth and studied the effect of intracellular polyamine modulation on the protein
translation state of the cells.
2. Materials and Methods
2.1. Materials
The following were purchased from Sigma-Aldrich (Dorset, UK): Dulbecco’s Modified
Eagle Medium (DMEM), Penicillin/Streptomycin, MEM non-essential amino acids 100×,
Trypsin-EDTA, L-glutamine, putrescine, spermidine, and spermine. Foetal bovine serum
(FBS) was from Gibco Life Technologies, Sao Paolo, Brazil. The protease and phosphatase
inhibitors cocktail were from Roche, Indianapolis, IN, USA. RIPA lysis buffer 10× from
Millipore, Burlington, VT, USA. The following antibodies were purchased from Abcam
Biotechnology, Cambridge, UK: rabbit polyclonal anti-β-actin (ab119716, 1:7500 dilution),
goat polyclonal anti-rabbit IgG-HRP (ab205718, 1:10,000 dilution), goat polyclonal anti-AZ1
(ab223481, 1:300), donkey anti-goat IgG H&L-HRP (ab97110, 1:2000). Mouse monoclonal
anti-ODC (sc-398116, 1:100 dilution) and goat anti-mouse IgG-HRP (sc-2005, 1:2500 dilu-
tion) antibodies were from Santa-Cruz Biotechnology, Heidelberg, Germany.
2.2. Experimental Procedures
2.2.1. Cell Culture
The human breast cancer cell lines MCF-7 and MDA-MB-231 (from ECACC) were
used in this study. The cells were grown under standard conditions of 37 ◦C and 5%
CO2 in T75-cm2 flasks containing 15 mL DMEM supplemented with 10% (v/v) FBS, 1%
(v/v) penicillin/streptomycin, and 1% (v/v) L-glutamine (for MCF-7 medium was further
supplemented with 1% (v/v) non-essential amino acids). In experiments involving addition
of exogenous polyamines to the cells, 1 mM aminoguanidine was also added to the growth
media to inhibit amine oxidases present in the complete growth medium.
2.2.2. Growth Determination
Cells were grown in 6 cm plates in duplicate and harvested at 4 h and at every 24
or 48 h up to 312 h depending on the experiment. At the indicated time point, cells were
harvested by trypsin-EDTA method, transferred to 15 mL tube, and centrifuged for 5 min
at 250 gav. The supernatant was discarded, and the cell pellet resuspended in 1 mL of
complete growth medium. A total of 100 µL of this suspension was sampled for cell
counting by trypan-blue exclusion assay. The remaining 900 µL was centrifuged and the
supernatant discarded. The cell pellet was washed twice in 2 mL PBS and lysed with 0.2 M
perchloric acid (PCA) on ice for 30 min for polyamine extraction and protein precipitation.
2.2.3. Protein Quantification
Protein was quantified by modification of Lowry et al. [18] method. A bovine serum
albumin (BSA) standard curve was prepared in the range 0 to 250 µg/mL in 0.3 M NaOH.
Both samples and standards were plated in a 96 well flat-bottom plate and exposed to
a basic solution containing Cu++ for 10 min prior to addition of 0.13 M Folin-Ciocalteau
reagent and incubated in the dark for 30 min. Plate was read using a Tecan Sunrise
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spectrophotometric microplate reader (Mannedorf, Switzerland). Total protein content was
expressed as mg/culture.
2.2.4. Polyamine Quantification
Polyamine content was quantified by LC-MS/MS (liquid chromatography–mass
spectrometry) as previously described [19]. Briefly, 200 µL of samples and polyamine
standards were placed in reaction tubes, 10 µL of 100 µM of 1,7-diaminoheptane was
added to each tube as internal standard, plus 50 µL of 1 g/mL sodium carbonate and
500 µL of freshly prepared 10 mg/mL dansyl chloride in acetone. Tubes were left overnight
at 37 ◦C. The next day, 0.5 mL of toluene was added to extract the dansylated products.
The organic phase was evaporated to dryness under N2 flow; the aqueous phase was
reconstituted in 200 µL methanol and vortex mixed for 10 s. This was then analyzed
using liquid chromatography in tandem with mass spectrometry (Thermo Scientific, Hemel
Hempstead, UK). Results were expressed in nmol and normalized with total protein content
for each sample.
2.2.5. Quantification of Intracellular DFMO
Intracellular DFMO content after cell exposure was quantified by LC-MS/MS using a
protocol developed by our group as part of this study.
DFMO stock (10 mM) was prepared in 0.2 M PCA and diluted to 2 mM in PCA.
DFMO calibration standards were prepared from this stock using the PCA cell extract from
an untreated control to minimize matrix effects during analysis. DFMO standards were
prepared in the range 0–20 µM with 50 µL of samples and standards transferred to reaction
tubes, followed by the addition of 150 µL of methanol. The tubes were vortex-mixed and
centrifuged at 21,000 gav for 5 min. 30 µL of the supernatant from each tube was transferred
to respective well of a 96-well plate and analyzed using a Thermo Surveyor–TSQ Quantum
system. The column was a Hichrom 3.5µ HIRPB (150 × 2.1 mm) with a mobile phase
consisting of 5% water and 95% methanol, both containing 0.1% formic acid, at a flow rate
of 0.2 mL/min. The column temperature was maintained at 50 ◦C and the autosampler tray
temperature at 4 ◦C with an injection volume of 2 µL. The mass spectrometer conditions
were set as follows: ionization mode: ESI in positive ion mode, spray voltage: 4000 V,
sheath gas: 50, auxiliary: 0, capillary temp: 375 ◦C, tuned tube lens: tuned value, skimmer
offset: −8 V, collision pressure: 1.8 mTorr. Single reaction monitoring was used for the
detection of DFMO with the SRM scan filter set at m/z 183.0–100.1 and a collision energy
of 28 V. DFMO eluted at 1.7 min and the total run time for analysis was 2.2 min.
Calibration curves were analyzed using weighted least squares linear regression with
a 1/X2 weighting. Results were expressed in nmol and normalized with total protein for
each sample.
2.2.6. Colony Formation Assay
Cells were seeded in 6 cm dishes for 24 h and treated with drug concentrations for 48 h.
Thereafter, cells were harvested and counted. About 500 cells for each treatment per dish
were re-seeded in duplicates in a 6 cm dish. Plates were left in a sealed incubator for at least
2 weeks or for eight cycles of generation time. At the completion of incubation, the culture
medium in each plate was carefully removed and the cell monolayer rinsed with PBS. The
cells were stained and fixed in 2 mL 0.5% (w/v) crystal violet solution in 50% methanol
(v/v in dH2O) for 30 min. The plates were carefully rinsed with tap water and left to dry
in normal air at room temperature. Colonies containing 50 cells or more were counted
under a Carl ZeissTM Stemi 2000-C stereo microscope (Jena, Germany) as representative
of surviving clonogenic cells. The surviving fraction was determined according to the
formula reported by Franken et al. [20].
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The surviving fraction is the number of colonies that arise from a single cell after cells
were treated with the respective drugs. The surviving fraction was expressed in terms of
the plating efficiency for individual treatment taken at 4 h post re-seeding.
Surviving fraction (%) =
number of colonies formed after treatment
number of cells seeded
× plating efficiency.
2.2.7. Western Blot
Cells were seeded and exposed to the respective drug treatment. After drug exposure,
cells were harvested and lysed on ice with ice-cold RIPA lysis buffer containing protease
and phosphatase inhibitors. Cell lysates were centrifuged at 17,000× g for 15 min at 4 ◦C.
The protein content of the supernatant was quantified by BCA protein assay kit according to
the manufacturer’s instructions (Pierce BCA Protein Assay Kit, Thermo Scientific, Rockford,
IL, USA). Samples containing equal amount of protein (30 µg) were separated on SDS-PAGE
(12% gel) and transferred to a nitrocellulose membrane overnight at 25 V. The membrane
was blocked in 5% (w/v) fat-free milk in PBS-Tween-20 (0.1% (v/v)) for 1 h, after which
membrane was incubated with primary antibodies for 3 h at room temperature. After
washing three times for 5 min in PBST, the membrane was incubated with secondary
antibodies conjugated HRP for 1 h at room temperature. After incubation, the membrane
was washed three times for 5 min in PBST, followed by development using enhanced
chemiluminescence substrate (SuperSignal West Dura, Thermo Scientific, Rockford, IL,
USA). Blot images were detected by Genoplex Bio Imager (VWR, Radnor, PA, USA). The
images were quantified by measuring the intensity of correctly-sized bands using ImageJ
software and normalized to the actin band intensity for all experiments.
2.2.8. Polysome Analysis
Cells were seeded and treated with respective drugs based on the experiment. After
drug exposure, cells were briefly treated with 100 µg/mL cycloheximide for 15 min, rinsed
in cycloheximide containing PBS, and detached by trypsinization. Cells were collected
by centrifugation and the pellet was washed twice in ice-cold PBS containing 100 µg/mL
cycloheximide, resuspended in 500 µL of complete lysis buffer [25 mM Tris-HCl (pH 7.4),
50 mM KCl, 5 mM MgCl2, 2 mM DTT, 100 µg/mL cyclohexamide and 200 µg/mL heparin,
1% triton-100, 1% sodium deoxycholate, and protease inhibitor]. Cells were lysed by
pumping the solution up and down a 25-gauge needle three times and left on ice for 20 min
while vortexing intermittently. Tubes were centrifuged at 17,000 gav for 15 min at 4 ◦C.
Total protein in the supernatant was estimated on nanodrop at 280 nm. Equal amount
of each samples corresponding to 20 OD was carefully layered onto 11 mL 15–50% (w/v)
sucrose gradient containing [25 mM Tris-HCl (pH 7.4), 50 mM KCl, 5 mM MgCl2, 2 mM
DTT, 100 µg/mL cyclohexamide, and 200 µg/mL heparin] in polycarbonate tubes. The
tubes were ultra-centrifuged at 270,900 gav for 2 h 15 min at 4 ◦C. Following centrifugation,
gradients were unloaded from the top by pumping 60% sucrose solution containing 0.05%
bromophenol blue to the bottom of each tube. The content of each gradient was measured
by UV absorbance using an Optical Unit UV-1 at a wavelength of 254 nm. Results were
recorded graphically using a chart recorder. All equipment was from Pharmacia Biotech,
Uppsala, Sweden.
2.3. Statistical Analysis
Statistical analysis was performed using Graphpad Prism software version 7. Values
shown as the mean of all replicates ± S.E.M (standard error of the mean) in which the
number of independent experiments was equal or more than three. Values were analyzed
by ANOVA with Dunnett’s post-test or by Students’ t-test. A p value less than 0.05 was
considered statistically significant. Where the number of independent experiments were
less than three, values shown are mean ± range.
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3. Results
3.1. Polyamine Pathway Inhibition Affects Breast Cancer Subtypes Differentially
Initial studies characterized the growth (as measured by the total cell number) re-
sponses of the two breast cancer cell lines to polyamine pathway inhibition. Exposure
of both ER+ MCF-7 and the ER- MDA-MB-231 cells to 5 mM DFMO caused almost 60%
decrease in intracellular polyamine content after 48 h (Table 1). However, the effect on
growth was less significant (Figure 1), with less than 15% decrease in total cell number
observed in both cell lines (Table 1). This suggests that the effects of DFMO exposure on cell
growth is gradual and develops over time. At longer exposure however, DFMO induced
a cytostatic response in the MCF-7 cells but only decreased the growth rate (i.e., the total
cell number) in the MDA-MB-231 cells within the period of growth determination. This
thus suggests that the ER+ MCF-7 cells, which have higher polyamine content (Table 1),
are more sensitive to polyamine pathway inhibition than the ER- MDA-MB-231 cells.
Table 1. Effect of DFMO on polyamine content of MCF7 and MDA-MB-231 cells. Polyamine content of 0.2 M perchloric
acid cell extract of MDA-MB-231 and MCF-7 cells was analyzed by LC-MS. Values shown are mean ± S.E.M, n = 3−4
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Figure 1. Time course of polyamine depletion on growth response of breast cancer cells. MDA-MB-
231 and MCF-7 cells were cultured in growth media treated with DFMO and total cell numbers were 
determined every 48 h. Values shown are mean ± S.E.M, n = 3–4 with 2 replicates per treatment per 
independent experiment and analyzed by Students’ t-test, *** p < 0.001 compared to the untreated 
control. Arrows pointing down indicate points of DFMO addition and replenishment at 5 mM in 
the growth media as the media is refreshed. 
  
Figure 1. Time course of polyamine depletion on growth response of breast cancer cells. MDA-MB-231 and MCF-7 cells were
cultured in growth media treated with DFMO and total cell numbers were determined every 48 h. Values shown are mean
± S.E.M, n = 3–4 with 2 replicates per treatment per independent experiment and analyzed by Students’ t-test, *** p < 0.001
compared to the untreated control. Arrows pointing down indicate points of DFMO addition and replenishment at 5 mM in
the growth media as the media s refreshed.
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To further determine the responses of the two breast cancer cell subtypes to polyamine
pathway inhibition, a survival assay was used to determine the colony formation of the
cell lines after exposure to varying DFMO concentrations.
Similar to the effects on cell growth, both cell lines showed differential colony forma-
tion ability after exposure to varying DFMO concentrations. In MCF-7, DFMO exposure
significantly inhibited colony formation compared to the MDA-MB-231 cells. MCF-7 cells
treated with 50 µM (0.05 mM) and 0.5 mM DFMO showed significant inhibition in the
number of colonies formed compared to MDA-MB-231 cells, where colony formation was
not affected by these DFMO concentrations (Figure 2). This further indicates the greater
susceptibility of MCF-7 cells to polyamine pathway inhibition. At 5 mM however, DFMO
exposure completely inhibits colony formation in both cell lines.
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Figure 2. Effects of DFMO exposure on colony formation in breast cancer cells. Cells were seeded 
in 6 cm dishes at a density of 2.4 × 104/cm2. Medium was refreshed after 24 h with varying DFMO 
concentrations and grown for 48 h. Thereafter cells were reseeded in 6 cm dish at 500 cells/dish 
without DFMO and incubated for 2 weeks. After incubation, cells were processed as described in 
Section 2.2.6. Result shown are mean ± S.E.M, (n = 3) with 2 replicates per treatment per 
independent experiments, * p < 0.05, *** p < 0.001 compared to the untreated control. 
  
Figure 2. Effects of DFMO exposure on colony formation in breast cancer cells. Cells were seeded in 6 cm dishes at a density
of 2.4 × 104/cm2. Medium was refreshed after 24 h with varying DFMO concentrations and grown for 48 h. Thereafter
cells were reseeded in 6 cm ish at 500 cells/dish wi hout DFMO and incubated for 2 weeks. After incubation, cells
were processed as described in Se tion 2.2.6. Result shown are me n ± S.E.M, (n = 3) with 2 replicates per treatment per
independent experiments, * p < 0.05, *** p < 0.001 compared to the untreated control.
3.2. DFMO Withdrawal Fails to Rescue Cell Growth Inhibition
To further characterize the polyamine and growth responses of the less sensitive
ER-MDA-MB-231 cells to polyamine pathway inhibition, the effect of short (48 h) and
continuous DFMO exposures were considered and compared to untreated control. In the
short exposure condition, DFMO (at 5 mM) was withdrawn from the culture medium after
the initial 48 h exposure and the effect of this treatment was compared to cells that were
continuously exposed to DFMO and with untreated cells.
DFMO withdrawal failed to rescue the growth and induced cytostatic effects similar to
that observed in cells that were continuously exposed to DFMO (Figure 3a). Also, there was
no difference in intracellular polyamine content in cells treated with DFMO for short time
and those treated for a longer time, although the total polyamine content in both exposures
was significantly lower than in the untreated cells (Figure 3b). Western blot analysis of
the ODC protein level showed a gradual decrease with increased time in culture but no
changes in the AZ (a negative regulator of ODC) protein level at both treatment conditions
(Figure 3c,d). This suggests that the DFMO, although only present in the medium for 48 h,
had long-term effects on growth and polyamine metabolism in the cell.
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Intracellular DFMO analysis showed build-up of DFMO content in cells that were
continuously exposed to DFMO (Table 2). In cells treated with DFMO for 48 h, there was a
gradual decrease in DFMO content after withdrawal from the culture medium, but residual
DFMO remained measurable in the cell (Table 2) and may be responsible for the polyamine
and growth responses observed in these cells.
Table 2. Intracellular DFMO content of MDA-MB-231 cells after withdrawal from growth medium.
DFMO content from the 0.2 M perchloric acid cell-soluble fraction was analyzed by LC–MS. Values
shown are mean ± range (n = 2) with 2 replicates per treatment per time point.





















Biomolecules 2021, 11, 743 8 of 14
3.3. Exogenous Polyamines Reversed Growth Inhibition
To find appropriate conditions to restore intracellular polyamines to the level needed
for cell proliferation, cells that had been pre-treated with 5 mM DFMO were further
incubated with exogenous polyamines at different concentrations. After 48 and 72 h of
polyamine exposure, cell number was determined, and polyamine content measured.
All exogenous polyamines reversed DFMO growth inhibition. In MCF-7 cells, pu-
trescine addition restored growth to 70% of the untreated control after 48 and 72 h exposure
(Figure 4a). Similarly, spermidine reversed growth inhibition in a dose-dependent manner
to almost 80% of the untreated control at the highest spermidine concentration (Figure 4b).
Exogenous spermine (Figure 4c) caused growth recovery similar to that seen with pu-
trescine. Similar results were obtained for MDA-MB-231 cells (Supplementary data 1).
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putrescine also restored intracellular spermidine content with no changes in the spermine 
content of the cells (Figure 5a). Similarly, exogenous spermidine following DFMO pre-
treatment caused an increase in the spermidine content with no changes in the putrescine 
and spermine content (Figure 5b). Spermine addition following initial polyamine depletion 
also caused an increase in spermidine content (Figure 5c). Both putrescine and spermidine 
additions caused greater increases in intracellular putrescine and spermidine content in 
MCF-7 cells than in MDA-MB-231 cells (Figure 5a,b and Supplementary data 2). 
Spermine addition also caused an increase in the spermine content but no measurable 
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Figure 4. Effect of exogenous polyamines on growth of MCF-7 cells. MCF-7 cells were pre-treated with 5 mM DFMO
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Polyamine analysis, following cell treatment with DFMO and exogenous putrescine,
showed a dose-dependent increase in intracellular putrescine content. The increase in
putrescine also restored intracellular spermidine content with no changes in the spermine
content of the cells (Figure 5a). Similarly, exogenous spermidine following DFMO pre-
treatment caused an increase in the spermidine content with no changes in the putrescine
and spermine content (Figure 5b). Spermine addition following initial polyamine depletion
also caused an increase in spermidine content (Figure 5c). Both putrescine and spermidine
additions caused greater increases in intracellular putrescine and spermidine content in
MCF-7 cells than in MDA-MB-231 cells (Figure 5a,b and Supplementary data 2).
Spermine addition also caused an increase in the spermine content but no measurable
increase in the putrescine content of the cells (Figure 5c). The increase in the spermidine
content by exogenous putrescine and spermine with no changes in both putrescine and
spermine content by exogenous spermidine suggests that the growth recovery occurring
due to polyamines is partly dependent on the spermidine content of the cell.
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Figure 5. Intracellular polyamine content of MCF-7 cells after exogenous polyamine additions. MCF-7 cells were pre-
treated with 5mM DFMO for 48 h, thereafter cells were treated with different concentrations of polyamines as indicated, 
following which cells were harvested and polyamines quantified. (a) polyamine content after exogenous putrescine 
addition (b) polyamine content after exogenous spermidine addition (c) polyamine content after exogenous spermine 
addition. Values shown are mean ± range (n = 2) with 2 replicates per treatment. 
3.4. Exogenous Polyamines Reversed Translation Inhibition 
As cell growth is linked to protein synthesis and general translation state of a cell, the 
effect of this intracellular polyamine modulation on general translation state of the cells 
was determined and compared with the untreated control cells using polysome 
distribution analysis. The polysome profile revealed a substantial inhibition of translation 
in the cells by DFMO exposure as seen with the decrease in heavier polysome peaks 
(Figure 6a). A similar result was also seen in the MDA-MB-231 cells (Supplementary data 
3). The DFMO treatment also caused a decrease in the polysome to monosome (p/m) ratio 
(Figure 6b) as estimated for the area under curve, an indication of inhibition of translation 
initiation following polyamine depletion. However, when spermidine was added to the 
Figure 5. Intracellular polyamine content of MCF-7 cells after exogenous polyamine additions. MCF-7 cells were pre-treated
with 5mM DFMO for 48 h, thereafter cells were treated with different concentrations of polyamines as indicated, following
which cells were harvested and polyamines quantified. (a) polyamine content after exogenous putrescine addition (b)
polyamine content after exogenous spermidine addition (c) polyamine content after exogenous spermine addition. Values
shown are mean ± range (n = 2) with 2 replicates per treatment.
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3.4. Exogenous Polyamines Reversed Translation Inhibition
As cell growth is linked to protein synthesis and general translation state of a cell, the
effect of this intracellular polyamine modulation on general translation state of the cells
was determined and compared with the untreated control cells using polysome distribution
analysis. The polysome profile revealed a substantial inhibition of translation in the cells
by DFMO exposure as seen with the decrease in heavier polysome peaks (Figure 6a). A
similar result was also seen in the MDA-MB-231 cells (Supplementary data 3). The DFMO
treatment also caused a decrease in the polysome to monosome (p/m) ratio (Figure 6b)
as estimated for the area under curve, an indication of inhibition of translation initiation
following polyamine depletion. However, when spermidine was added to the cells for 24 h
after the initial DFMO pre-treatment, polysome analysis revealed a substantial increase
in the heavy polysomes with a noticeable decrease in the monosome peak (Figure 6c).
Estimating the area under curve showed an increase in p/m ratio by spermidine addition
compared to DFMO treated cells (Figure 6d), suggesting an increase in translation initiation
by exogenous spermidine.
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4. Discussion
Research relating to polyamines and polyamine metabolism, especially in cancer, has
received significant attention in recent decades owing to the important roles of polyamines
in cellular and physiological processes. Functions attributed to polyamines range from
regulation of gene expression to control of apoptosis, cell cycle progression, regulation of
signaling pathways, and cell proliferation [21–25] with these contributing to cell growth,
particularly in cancer. While a link between elevated polyamine content and poor prognosis
of breast cancer has been established by various studies [14,26], breast cancer patients do
not seem to benefit from mono-therapeutic inhibition of the polyamine pathway [27–29].
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However, in a clinical trial study by O’Shaughnessy, et al., one patient with metastatic
breast cancer was found to have stability of liver metastasis for eighteen months on DFMO
therapy [28], suggesting that some breast cancer patients might benefit from therapy that
targets polyamine metabolism.
The main reason for the general poor efficacy of polyamine pathway inhibitors in
cancer treatment is attributed to the compensatory polyamine uptake by the tumour cells
from the polyamines present in the diet and polyamines produced by the microbiota in
the gut. To counter this, a polyamine blocking therapy that combines both polyamine
pathway inhibitor (DFMO) and inhibitor of polyamine transporter (AMXT 1501 dicaprate)
has since been developed [30] and is in phase 1 clinical trials for treating patients with
advanced solid tumours (ClinicalTrials.gov. Identifier: NCT03536728). This polyamine
blocking therapy might thus serves a better therapeutic benefit in breast cancer treatment
than the use of monotherapy targeting polyamine pathway inhibition, however, there is
a need to determine which breast cancer, based on the hormone receptor status, might
benefit most from therapy that depletes intracellular polyamine content.
In this study, the responses of two breast cancer cells of different hormone receptor
status to intracellular polyamine modulation was compared. It was shown that the ER+
MCF-7 cells, with higher polyamine content, showed greater growth inhibition to intracel-
lular polyamine depletion than the ER- MDA-MB-231 cells. This greater growth inhibition
was further supported by the greater inhibition of colony formation by the different con-
centrations of DFMO used in the MCF-7 cells. MCF-7 cells also showed higher intracellular
polyamine content following exposure to exogenous polyamine than did the MDA-MB-231
cells, suggesting that the ER+ MCF-7 cells are more dependent on polyamines for pro-
liferation and are more susceptible to conditions that limit polyamine content. A study
by Kremmer, et al. also suggests MCF-7 cells to be sensitive to the anti-tumour effects of
polyamine depletion [31]. Similarly, in the ER+ ZR-75 breast cancer cell line, polyamine
depletion by DFMO was found to abrogate the growth effect of oestradiol [32]. These
studies indicate greater dependence of hormone receptor positive (HR+) breast cancer
cells on polyamines for proliferation, which thus suggests that patients with HR+ breast
cancer subtype may benefit from therapies that decrease tumour polyamine content. This
potential polyamine limiting therapy in HR-positive breast cancer subtype warrants further
investigation that involves the use of other breast cancer cell lines and animal models of
the different hormone receptor status.
In addition to the differential hormone receptor status of the two cell lines used in
this study, differences in the expression of key proteins involved in cell proliferation and
survival, such as p53 and c-Myc, may contribute to the differential growth responses to
polyamine modulation. MDA-MB-231 cell expresses mutated TP53 gene, while MCF-7
cell expresses wild-type TP53 gene [33]. Both cell lines also have elevated c-Myc protein,
although the mechanism of c-Myc elevation differs. In MCF-7, elevated c-Myc protein
is linked to oestrogen/oestrogen receptor stabilization of c-Myc protein half-life [34]. In
MDA-MB-231 cells, the c-Myc protein level is associated with decreased Axin1 gene ex-
pression [35]. In MCF-7 cell, oestrogen also positively regulates ODC1 gene expression
and protein activity [7]. c-Myc on the other hand positively regulates ODC1 gene expres-
sion [36,37] and along with spermine synthase promotes cancer cell survival [38]. Thus,
differences in gene expression patterns together with the hormone receptor status of the
cells may contribute to their differential responses to polyamine pathway inhibition and
may help predict the sensitivity of breast cancers to polyamine targeting therapy.
One important observation in this study was that residual DFMO remained measur-
able in the cell several days after its withdrawal from the culture medium. This finding is
particularly interesting and, to the best of our knowledge, this is the first study that has
measured intracellular DFMO content after in-vitro exposure. This knowledge of persistent
DFMO in cells with accompanied decrease in polyamine content and cell growth will be
useful in future cancer therapeutic settings that target polyamine pathway for inhibition.
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In determining the requirement of the cells for each polyamine for proliferation, data
from this study suggests that the growth effects of the polyamines are partly dependent
on the spermidine content of the cell. This observation was supported by the complete
restoration of spermidine content by exogeneous putrescine and increase in spermidine
by exogenous spermine with little or no change in putrescine and spermine content by
exogenous spermidine. This dependence on spermidine may be attributed to its require-
ment in hypusination/activation of eukaryotic translation initiation/elongation factor 5A
(eIF5A), which requires the presence of spermidine for activation. Activation of eIF5A
is needed in protein translation, particularly the translation of proteins with polyproline
tracts or PPX (where X may be Gly, Trp, Asp, or Asn) [39,40]. These proteins are known to
be involved in metabolic processes that promote cell proliferation [41] and hence cancer
cell growth. Since breast cancers have elevated polyamines and are more dependent on
spermidine for proliferation, therefore, another approach to targeting polyamine biology
in breast cancer treatment could be to inhibit the link between spermidine and eIF5A by
inhibiting the enzymes (deoxyhypusine synthase and deoxyhypusine hydroxylase) that
catalyze the hypusination reaction.
Although a limited model system of each hormone receptor status of the breast cancer
subtype was used in this study, the data presented here nevertheless provides strong
evidence that breast cancer cells respond to polyamine inhibition differentially and that
a non-linear relationship exists between the polyamines in promoting the cancer cell
growth. This data also provides the basis for further characterization of more models of
breast cancer to polyamine targeting therapy. While higher concentrations of DFMO than
clinically achievable in dosing were used in this study, these concentrations were chosen
based on prior literature search and previous data from our lab.
In conclusion, we showed that breast cancer cell growth in-vivo is causally linked to
their polyamine content and, the sensitivity of the cells to growth inhibition by agent(s) that
limit polyamine content is partly dependent on the hormone receptor status of the cells.
We also showed that the growth recovery effects of exogenous polyamines were partly
dependent on their conversion to spermidine. Polyamine depletion inhibits translation
initiation and exogenous spermidine was able to reverse this inhibition in the breast cancer
cells. Finally, we suggest that from these results, targeting polyamine metabolisms might
be beneficial in ER-positive breast cancers.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biom11050743/s1, Supplementary data 1: Effect of exogenous polyamines on MDA-MB-232
cells growth: title, Supplementary data 2: Intracellular polyamine content of MDA-MB-231 cells
after exogenous polyamines additions, Supplementary data 3: Effects of polyamine depletion on
translation state of MDA-MB-231 cells.
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